Becton, Dickinson and Company (NYSE:BDX – Get Rating) – Research analysts at Jefferies Financial Group reduced their Q2 2023 EPS estimates for Becton, Dickinson and in a report issued on Thursday, February 2nd. Jefferies Financial Group analyst M. Taylor now anticipates that the medical instruments supplier will earn $2.78 per share for the quarter, down from their prior estimate of $2.89. The consensus estimate for Becton, Dickinson and's current full-year earnings is $12.12 per share. Jefferies Financial Group also issued estimates for Becton, Dickinson and's Q3 2023 earnings at $3.09 EPS, Q4 2023 earnings at $3.40 EPS and FY2025 earnings at $15.23 EPS.

Becton, Dickinson and (NYSE:BDX – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.30. The business had revenue of $4.59 billion during the quarter, compared to analyst estimates of $4.59 billion. Becton, Dickinson and had a net margin of 8.47% and a return on equity of 13.52%. The firm's quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter last year, the business earned $3.64 EPS.

Becton, Dickinson and Stock Down 1.1 %

Shares of NYSE BDX opened at $245.84 on Monday. The company has a 50 day simple moving average of $251.67 and a 200 day simple moving average of $244.53. The firm has a market cap of $69.88 billion, a PE ratio of 46.38, a price-to-earnings-growth ratio of 2.11 and a beta of 0.54. Becton, Dickinson and has a 1 year low of $215.90 and a 1 year high of $280.62. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.07 and a quick ratio of 0.63.

Institutional Investors Weigh In On Becton, Dickinson and

Several large investors have recently added to or reduced their stakes in BDX. Red Tortoise LLC purchased a new position in Becton, Dickinson and during the 4th quarter valued at about $25,000. Legend Financial Advisors Inc. lifted its position in Becton, Dickinson and by 105.6% in the 4th quarter. Legend Financial Advisors Inc. now owns 111 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 57 shares during the last quarter. Trifecta Capital Advisors LLC bought a new stake in Becton, Dickinson and in the fourth quarter valued at approximately $31,000. Western Pacific Wealth Management LP bought a new stake in Becton, Dickinson and in the third quarter valued at approximately $30,000. Finally, Chilton Capital Management LLC bought a new stake in Becton, Dickinson and in the second quarter valued at approximately $39,000. Hedge funds and other institutional investors own 87.08% of the company's stock.

Becton, Dickinson and Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Investors of record on Friday, March 10th will be issued a $0.91 dividend. This represents a $3.64 annualized dividend and a yield of 1.48%. The ex-dividend date is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio (DPR) is currently 68.68%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Read More

• Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
• Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.